Related by context. All words. (Click for frequent words.) 71 Phase Ib II 70 GVAX 70 phase IIb clinical 70 Phase Ib clinical 70 axitinib 69 pertuzumab 69 EndoTAG TM -1 69 elotuzumab 69 phase IIa clinical 69 elacytarabine 69 PSMA ADC 69 EFAPROXYN 69 ATL# [001] 68 YONDELIS 68 PXD# 68 ASA# 68 Dacogen injection 68 obatoclax 68 sapacitabine 68 oral ridaforolimus 68 enzastaurin 68 alvespimycin 68 Asentar 68 tanespimycin 68 afatinib 68 T DM1 68 LUX Lung 67 CoFactor 67 goserelin 67 Phase IIIb clinical 67 ToGA 67 pomalidomide 67 Phase #b/#a 67 adecatumumab 67 ixabepilone 67 MAGE A3 ASCI 67 ELACYT 67 Amrubicin 67 Azedra 67 glufosfamide 67 BCIRG 67 TNFerade 66 dacetuzumab 66 mapatumumab 66 AEG# 66 phase IIb trial 66 Tavocept 66 vidofludimus 66 custirsen 66 MGCD# [001] 66 picoplatin 66 HuLuc# 66 HGS ETR1 66 decitabine 66 INCB# [001] 66 MERLIN TIMI 66 Tesmilifene 66 Virulizin ® 66 Targretin 66 pegylated liposomal doxorubicin 66 phase IIb 66 SinuNase 66 Bicifadine 66 TORISEL 66 PROSTVAC ® 66 IMA# 66 iniparib 66 ridaforolimus 65 ganetespib 65 ZYBRESTAT 65 eprotirome 65 BRIM2 65 HuMax CD# 65 Virulizin R 65 eniluracil 65 HGS# 65 indibulin 65 Phase Ib 65 Allovectin 7 65 APPRAISE 65 thymalfasin 65 Phase Ib study 65 metastatic castration resistant 65 Neuradiab 65 OPAXIO 65 OXi# 65 Symadex 65 STRIDE PD 65 NATRECOR R 65 UVIDEM 65 Phase IIb III 65 randomized Phase 2b 65 Phase III randomized controlled 65 GVAX immunotherapy 65 Vectibix panitumumab 65 OncoVEX GM CSF 65 PEG SN# 65 MGd 65 lintuzumab 65 standard chemotherapy regimen 65 elesclomol 65 Proxinium TM 65 Avastin bevacizumab 65 Velcade bortezomib 65 Dacogen decitabine 65 Troxatyl 65 aflibercept 65 LibiGel Phase III 65 Ixempra 65 EOquin 65 deforolimus 65 riociguat 65 OvaRex ® MAb 65 registrational 65 abiraterone acetate 64 rNAPc2 64 Imprime PGG 64 CYT# 64 zalutumumab 64 Vectibix monotherapy 64 mertansine 64 IMC A# 64 Phase 2a trial 64 Panzem 64 Revlimid lenalidomide 64 CBLC# 64 Phase IIb clinical 64 figitumumab 64 Cloretazine ® 64 palifosfamide 64 CA4P 64 BRAF inhibitor 64 AP# [003] 64 CHAMPION PCI 64 Allovectin 7 ® 64 SUTENT 64 ACAPODENE 64 Genasense 64 lumiliximab 64 Cloretazine 64 ThGRF 64 Phase #b/#a clinical 64 trastuzumab emtansine T DM1 64 belinostat 64 Bezielle 64 Hycamtin 64 Viramidine 64 pradefovir 64 ocrelizumab 64 sunitinib 64 Ceflatonin 64 Phase 1b 64 CIMZIA ™ 64 sunitinib malate 64 seliciclib 64 muraglitazar 64 atacicept 64 AEGR 64 AVOREN 64 Taxotere ® 64 BRIM3 64 forodesine 64 OncoVEX 64 Novartis Zometa 64 Phase 1b trial 64 Ocrelizumab 64 Exelixis XL# 64 clofarabine 64 dose escalation Phase 64 low dose cytarabine 64 carboplatin paclitaxel 64 valopicitabine 64 TRISENOX 64 nimotuzumab 64 relapsed multiple myeloma 64 FOLOTYN ® 64 Amplimexon 64 metastatic hormone refractory 64 Phase 2b study 64 EndoTAGTM 1 63 MDV# 63 cangrelor 63 ELOXATIN 63 NVA# 63 bicifadine 63 infusional 5-FU/LV 63 MEK inhibitor RDEA# 63 Phase IIa trial 63 dirucotide 63 XmAb# 63 preclinically 63 Archexin 63 Canvaxin 63 CR# vcMMAE 63 Pertuzumab 63 IMPACT IMmunotherapy 63 isavuconazole 63 bendamustine 63 Pemetrexed 63 Vectibix 63 dose escalation clinical 63 perifosine 63 Cloretazine R VNP#M 63 interferon gamma 1b 63 talabostat 63 randomized Phase IIb 63 olaparib 63 Dacogen 63 oral Xeloda 63 Irinotecan 63 nab paclitaxel 63 randomized controlled Phase 63 ZACTIMA 63 vandetanib 63 IMC #B 63 Corlux 63 AeroLEF TM 63 Tarceva TM 63 panitumumab 63 Phase 1b clinical 63 HuMax EGFr 63 Nexavar sorafenib 63 teriflunomide 63 bevacizumab Avastin 63 abiraterone 63 ularitide 63 celgosivir 63 multicenter Phase II 63 EOquin TM 63 pivotal bioequivalence 63 RE LY 63 Orazol 63 ofatumumab 63 clinical pharmacology studies 63 HER2 positive metastatic breast 63 midstage clinical 63 Aplidin 63 Fludara 63 Insegia 63 HRPC 63 randomized multicenter Phase III 63 APTIVUS 63 Folfox 63 AIM HIGH 63 SYMMETRY trial 63 Intravenous CP 63 HGS ETR2 63 JAK inhibitor 63 Onconase 63 Phase IIa trials 63 YERVOY 63 cediranib 63 otelixizumab 63 XL# SAR# 63 Androxal TM 63 Nexavar ® 63 zanolimumab 63 Telcyta 63 rindopepimut 63 TroVax 63 TYKERB 63 trastuzumab DM1 63 SUCCEED trial 63 relapsed ovarian cancer 63 Urocidin 63 registrational trial 63 regorafenib 63 TELCYTA 63 romidepsin 63 Randomized Phase II 63 Phase III metastatic melanoma 63 oral deforolimus 63 pitavastatin 63 neratinib 63 confirmatory Phase III 63 Æterna Zentaris 63 MYDICAR ® 62 Betaferon ® 62 Dextofisopam 62 phase IIa 62 azacitidine 62 Omnitarg 62 Vitaxin 62 Telatinib 62 Xelox 62 Mylotarg 62 phase Ib 62 tremelimumab 62 Sym# 62 tesetaxel 62 RSD# oral 62 placebo controlled clinical 62 Panitumumab 62 ADAGIO study 62 PhG alpha 1 62 lomitapide 62 XELOX 62 Glufosfamide 62 TEMODAL 62 PROCHYMAL 62 resminostat 62 veltuzumab 62 Marqibo 62 Phase Ia 62 PEP# [003] 62 Quinamed 62 velafermin 62 recurrent glioblastoma multiforme 62 vorinostat 62 methylnaltrexone 62 pharmacokinetic PK study 62 BIBW 62 ACCEDE 62 PRT# 62 Erbitux cetuximab 62 Prostate AdenoCarcinoma Treatment 62 Phase #/#a 62 TREANDA 62 BNC# 62 BAY #-# 62 Vernakalant 62 Fibrillex TM 62 Candesartan 62 Zolinza 62 Onrigin 62 CIMZIA TM 62 PROSTVAC TM 62 BioNumerik 62 OMP #M# 62 Ozarelix 62 Phase 2b clinical 62 Traficet EN 62 MAXY G# 62 Alocrest 62 Phase IIB 62 Panzem R NCD 62 fondaparinux 62 KRAS status 62 AVADO 62 brivaracetam 62 FOLOTYN 62 TheraCIM 62 randomized Phase III 62 faropenem 62 Virulizin 62 amrubicin 62 seliciclib CYC# 62 AZILECT ® 62 tipranavir 62 daclizumab 62 Phase 2b trial 62 tocilizumab 62 MoxDuo IR 62 HuMax CD4 62 Tarvacin 62 MYDICAR 62 AQ4N 62 sorafenib Nexavar 62 XYOTAX TM 62 Tyrima 62 MAA submission 62 Xcytrin 62 anastrozole 62 mycophenolate mofetil 62 relapsed MM 62 ISTODAX 62 Phase Ib IIa 62 radiation sensitizer 62 evaluating tivozanib 62 lorvotuzumab mertansine 62 Jevtana 62 temsirolimus 62 FTY# 62 PDE4 inhibitor 62 TOCOSOL Paclitaxel 62 R#/MEM # 62 ZOLINZA 62 pemetrexed 62 chemotherapeutic regimen 62 initiate Phase 1b 62 Vidaza 62 Sapacitabine 62 doxorubicin docetaxel 62 ZYBRESTAT fosbretabulin 62 Dasatinib 62 StemEx R 62 TACI Ig 62 subcutaneous PRO 62 viral kinetic 62 Aloxi injection 61 TBC# 61 phase Ib clinical 61 Tanespimycin 61 RE LY ® 61 HspE7 61 dose escalation 61 vosaroxin 61 docetaxel chemotherapy 61 erlotinib Tarceva 61 oral diclofenac 61 trabectedin 61 paclitaxel Taxol ® 61 lapatinib 61 Pixantrone 61 DXL# 61 M6G 61 CEQ# 61 CTAP# Capsules 61 bardoxolone 61 R# #mg BID 61 docetaxel 61 GVAX Pancreas Vaccine 61 phase 2a 61 Solorel 61 vinorelbine 61 XYOTAX 61 Vandetanib 61 cabazitaxel 61 IMGN# 61 gemcitabine cisplatin 61 ATACAND 61 GLP toxicology studies 61 Aflibercept 61 darapladib 61 metastatic HRPC 61 torezolid phosphate 61 Elitek 61 Xyotax 61 Elocalcitol 61 IL# PE#QQR 61 ELND# 61 ThermoDox R 61 JAK3 61 BZL# 61 ATL/TV# 61 samalizumab 61 oral FTY# 61 RhuDex ® 61 Azilect ® 61 FOLFIRI 61 Zerenex 61 PRIMO CABG 61 GFT# 61 fenofibric acid 61 tipifarnib 61 crizotinib PF # 61 LHRH antagonist 61 SUTENT ® 61 Theratope 61 Trastuzumab 61 RSD# 61 dose escalation phase 61 Natalizumab 61 ASONEP 61 anti leukemic 61 PD LID 61 mifamurtide 61 metastatic castrate resistant 61 ongoing Phase 1b 61 aleglitazar 61 TYGACIL 61 alvimopan 61 trastuzumab DM1 T DM1 61 PROMACTA 61 Apaziquone 61 placebo controlled Phase III 61 Ceplene/IL-2 61 Degarelix 61 lapatinib Tykerb 61 Temsirolimus 61 THALOMID 61 posaconazole 61 Octreolin 61 tramiprosate Alzhemed TM 61 Xanafide 61 CD# antibody [001] 61 sorafenib tablets 61 GLPG# 61 Fulvestrant 61 Neurodex 61 BST CarGel R 61 galiximab 61 Loramyc R 61 Lapatinib 61 Genasense ® 61 Nuvion 61 tecarfarin 61 ADVANCE PD 61 Xinlay 61 tezampanel 61 Perifosine 61 Tamibarotene 61 Phase IIb 61 vilazodone 61 ACZ# 61 teduglutide 61 RIGScan CR 61 PRECISE trial 61 vascular disrupting agent 61 sipuleucel T 61 cilengitide 61 Cleviprex TM clevidipine 61 mTOR inhibition 61 apaziquone 61 Erlotinib 61 iniparib BSI 61 L BLP# 61 Torisel 61 Doxil 61 GRN#L 61 NeuVax 61 TKM ApoB 61 AGGRASTAT ® 61 lesinurad 61 imetelstat 61 Fibrin Pad 61 budesonide foam 61 angiographic outcomes 61 blinatumomab 61 Evoltra 61 Ceflatonin ® 61 Phase IIb trials 61 ancrod 61 satraplatin 61 ProSavin 61 Nasulin 61 OHR/AVR# 61 CVac 61 Tarvacin TM 61 metaglidasen 61 PLK1 SNALP 61 CRD5 61 voreloxin 61 Onco TCS 61 lupus nephritis 61 relapsed refractory multiple myeloma 61 PTK ZK 61 reslizumab 61 incyclinide 61 Plicera 61 Aplidin R 61 IRX 2 61 atrasentan 61 MyVax R 61 BCX# 61 NXL# 61 APEX AMI trial 61 NUVIGIL 61 QVA# 61 vemurafenib 61 nonsmall cell lung cancer 61 Saforis 61 Vion Pharmaceuticals 60 TASQ 60 prostate cancer CRPC 60 Chrysalin 60 Prestara 60 HCV SPRINT 60 motesanib 60 CGEN # 60 ILLUMINATE 60 midstage trials 60 sevelamer 60 rhThrombin 60 AERx iDMS 60 CRMD# 60 Thalomid ® 60 Amigal 60 TTF Therapy 60 Phase III Pivotal 60 pivotal Phase III 60 OMAPRO 60 Fodosine 60 PF # [002] 60 vicriviroc 60 Dapagliflozin 60 Atiprimod 60 entinostat 60 pazopanib 60 Lenocta 60 blinded randomized placebo controlled 60 viral kinetics 60 DU #b 60 alogliptin 60 Urocidin TM 60 Cotara 60 topotecan 60 metastatic renal cell carcinoma 60 Diabetic Macular Edema 60 Phase III clinical 60 sorafenib Nexavar ® 60 enoximone 60 Phase 1b clinical trials 60 Syncria 60 Omacetaxine 60 SIR Spheres 60 EMPHASIS HF trial 60 senicapoc 60 bortezomib 60 tolevamer 60 ACOMPLIA R 60 PrevOnco 60 DAPT 60 TELINTRA 60 INTEGRILIN 60 CIMZIA TM certolizumab pegol 60 anti EGFR antibody 60 Laquinimod 60 Removab 60 PI3K/Akt pathway inhibitor 60 IMP# 60 telaprevir dosed 60 Cinquil 60 Folotyn 60 evaluating satraplatin 60 IPL# 60 Allovectin 7 R 60 Herceptin trastuzumab 60 JAK inhibitors 60 Vicinium TM 60 Vilazodone 60 SCCHN 60 CLARITY study 60 acyclovir Lauriad ® 60 Advexin 60 AZOR 60 ALS #-# 60 Gemcitabine 60 depsipeptide 60 VIDAZA 60 phase IIIb 60 CCX# 60 Phase IIb clinical trials 60 acyclovir Lauriad R 60 Zybrestat 60 multicenter Phase 60 oral rivaroxaban 60 plus dexamethasone 60 ALSYMPCA 60 PhosLo 60 Afatinib 60 Phase IIa clinical 60 Angiolix 60 Lu AA# 60 glatiramer 60 motavizumab 60 Myocet 60 Vidofludimus 60 Azacitidine 60 Targretin capsules 60 BEXXAR 60 NSABP 60 sorafenib 60 Mipomersen 60 Hycamtin ® 60 anticancer agent 60 TAXOTERE R 60 ONCONASE R 60 OvaRex R 60 GRNVAC1 60 ozarelix 60 Cethromycin 60 Ophena 60 gemcitabine 60 confirmatory clinical 60 mRCC 60 Pfizer Sutent 60 NEVO ™ 60 NEBIDO 60 anti angiogenic therapy 60 ONTARGET R 60 antiangiogenic therapy 60 Reverset 60 chemoradiotherapy 60 Phase III VISTA 60 nitazoxanide 60 Multaq R 60 Actilon 60 active comparator 60 bevacizumab Avastin ® 60 VIR# 60 bortezomib Velcade R 60 GRN# 60 DOXIL 60 AEterna 60 CRx 60 trastuzumab Herceptin 60 gemcitabine carboplatin 60 iSONEP 60 DP b# 60 cetrorelix 60 Bafetinib 60 Adjuvant chemotherapy 60 dacarbazine 60 Sorafenib 60 Pirfenidone 60 INTELENCE 60 ProLindac 60 Zevalin consolidation 60 Daclizumab 60 Elacytarabine 60 RLY# 60 monotherapy 60 antithrombotic 60 pediatric acute lymphoblastic 60 dose cohort 60 bicalutamide 60 Abraxane 60 gemcitabine chemotherapy 60 MOZOBIL 60 Doxil ® 60 Lung Rx 60 #ME# 60 Hepatocellular Carcinoma HCC 60 LymphoStat B 60 Lorianne Masuoka MD 60 Nanobody 60 OvaRex MAb 60 durable pain palliation 60 PRADAXA 60 PRX# 60 multicentre randomized 60 ADXS# 60 pharmacodynamic effects 60 ACCORD Lipid 60 biliary tract cancer 60 masitinib 60 S/GSK# 60 evaluating Actimmune 60 EchoCRT 60 APTIVUS r 60 trabedersen 60 Gemzar ® 60 Neulasta ® 60 CYT# potent vascular disrupting 60 plasma kallikrein inhibitor 60 tolvaptan 60 dose escalation trial 60 APOPTONE 60 Rebif ® 60 opioid induced bowel dysfunction 60 Ridaforolimus 60 confirmatory Phase 3 60 ACTIVE W 60 rALLy clinical trial 60 Apixaban 60 Viprinex 60 aclidinium bromide 60 p# biomarker 60 ponatinib 60 anticancer compound 60 PIX# [002] 60 Phase III psoriasis 60 fostamatinib 60 Cimzia TM 60 TroVax ® 60 randomized Phase 60 FOLFIRINOX 60 tamoxifen therapy 60 Sulonex 60 NOXAFIL 60 RITUXAN 60 KRAS mutations occur 60 alfimeprase 60 recurrent glioma 60 Panzem R 59 postoperative chemotherapy 59 CALGB 59 Pazopanib 59 abatacept 59 eltrombopag 59 iclaprim 59 SILENOR 59 ABSORB clinical 59 Ceflatonin R 59 HCV RESPOND 2 59 ARIKACE ™ 59 WILEX 59 SNT MC# 59 PCK# 59 Onrigin TM 59 sapacitabine CYC# 59 PROVENGE sipuleucel T 59 triphendiol 59 Reolysin 59 Pimavanserin 59 BEACOPP 59 liprotamase 59 Bevacizumab 59 TLK# 59 Scancell 59 NP2 Enkephalin 59 TriRima 59 Phase 1a clinical 59 Treanda 59 recurrent GBM 59 paclitaxel Taxol 59 carfilzomib 59 ORENCIA R 59 GW# [003] 59 Zactima 59 MEND CABG II 59 mCRC patients 59 Toraymyxin TM 59 paclitaxel poliglumex 59 PREOS 59 Randomized Phase 59 ENMD # 59 ENRICH trial 59 Aptivus ® 59 Ticagrelor 59 CCX# B 59 metastatic CRC 59 multicenter clinical 59 vismodegib 59 ISIS # 59 PRE SURGE 59 ORMD 59 neurologic progression 59 dimebon 59 HER2 positive breast cancer 59 HyQ 59 Phase #/#a trial 59 Phase 2a clinical 59 CRLX# 59 antitumor effect 59 Seliciclib 59 Phase III pivotal 59 bevacizumab 59 Bortezomib 59 Dose escalation 59 Pennsaid R 59 desvenlafaxine 59 idraparinux 59 PEG Interferon lambda 59 ONTARGET 59 DASISION 59 paclitaxel carboplatin 59 DSMB recommended 59 GAP #B# 59 BR.# 59 PSN# [002] 59 Zemplar Capsules 59 TOLAMBA 59 Exherin TM 59 Stimuvax R 59 Phase 2b 59 R roscovitine 59 ENDEAVOR III 59 ANCHOR trial 59 visilizumab 59 Vorapaxar 59 PHX# 59 febuxostat 59 GSK# [001] 59 Genentech Roche 59 Subgroup analysis 59 paliperidone ER 59 FOLPI 59 CytoFabTM 59 RAPAFLO 59 IIa trial 59 HoFH 59 REOLYSIN ® 59 PLX# 59 Satraplatin 59 ISENTRESS 59 invasive candidiasis 59 adjuvant endocrine therapy 59 canakinumab 59 Actimmune ® 59 ABSORB trial 59 metastatic RCC 59 KNS # 59 Dendreon Provenge 59 taxotere 59 trastuzumab Herceptin R 59 PROSTVAC VF 59 Cetrorelix 59 Argatroban 59 COPAXONE R 59 aclidinium 59 dexanabinol 59 cetuximab Erbitux 59 Cethrin 59 Voreloxin 59 Aurora kinase 59 VAPRISOL 59 oblimersen 59 bone metastasis 59 TMC# [002] 59 MICARDIS ® 59 PrevOnco ™ 59 Northera 59 cisplatin vinorelbine 59 baminercept 59 fosbretabulin 59 REVLIMID 59 solithromycin 59 PF # [001] 59 Dabigatran etexilate 59 docetaxel Taxotere R 59 Darusentan 59 elagolix 59 MabThera rituximab 59 ceftaroline 59 CD3 monoclonal antibody 59 LY# [003] 59 ThermoDox ® clinical 59 Aurexis 59 SERMs 59 UPLYSO 59 Phenoptin 59 Tykerb lapatinib 59 FOLFOX4 59 ISEL 59 FUSILEV 59 Campath alemtuzumab 59 APEX PD 59 Gefitinib 59 CDP# 59 Thorough QT 59 interferon beta therapy 59 ATAC Arimidex Tamoxifen Alone 59 Acapodene 59 paclitaxel Taxol R 59 clazosentan 59 Taxotere R 59 SCH # 59 ReN# 59 SAR# [004] 59 farletuzumab 59 bosentan 59 docetaxel Taxotere 59 Clavis Pharma 59 Alpharadin 59 oral antiviral 59 castration resistant prostate cancer 59 oncolytic vaccine 59 tramiprosate 59 estramustine 59 XGEVA 59 PROVENGE 59 zoledronic acid 59 VEGF Trap 59 Taxotere docetaxel 59 Sibutramine Cardiovascular Outcomes 59 placebo controlled Phase 59 INGN 59 AVONEX 59 boosted protease inhibitor 59 CaPre TM 59 Alemtuzumab 59 Eribulin 59 DSMB 59 CAELYX 59 Genz # 59 NOX E# 59 lixisenatide 59 Alvesco R 59 Angiox ® 59 Silodosin 59 Pixuvri 59 talactoferrin 59 therapeutic regimens 59 neoadjuvant therapy 59 antiplatelet agent 59 MEK inhibitor 59 gemcitabine Gemzar 59 Vascular Wrap 59 AVONEX ® 59 BLA filing 59 anticancer therapies 59 Kaplan Meier analysis 59 pegylated interferon alfa 2b 59 Azixa 59 Ranolazine 59 XL# [003] 59 R sorafenib tablets 59 Diamyd ® 59 PANVAC VF 59 double blinded placebo 59 Valsartan 59 omacetaxine mepesuccinate 59 Preos 59 TAXUS Element Stent System 59 bazedoxifene 59 Phase #b/#a trial 59 inhaled treprostinil 59 selective androgen receptor modulator 59 gefitinib Iressa 59 Tocosol Paclitaxel 59 Orathecin 59 Cytolin R 59 LT NS# 59 BLA submission 59 Gleevec resistant 59 NCCTG N# 59 refractory multiple myeloma